mRNA encoding an unspecified intrinsic coagulation pathway protein

The term mRNA encoding an unspecified intrinsic coagulation pathway protein refers to a category of therapeutic messenger RNA molecules designed to induce the expression of proteins within the intrinsic (contact activation) arm of the blood coagulation cascade. This pathway involves a series of proteolytic activations involving Factor XII, Factor XI, Factor IX, and Factor VIII, which collectively lead to the activation of Factor X and the eventual formation of a stable fibrin clot [1]. mRNA-based therapeutics in this space are primarily developed as protein replacement therapies for hereditary bleeding disorders, such as Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency) [2, 4]. These synthetic mRNAs are typically encapsulated in lipid nanoparticles for targeted delivery to the liver, where they utilize the host's cellular machinery to produce functional clotting factors [3]. While this approach represents a novel frontier in genomic medicine, the 'unspecified' nature of this entry indicates it is a broad classification rather than a single molecular target [3]. Clinical monitoring typically involves measuring the activated partial thromboplastin time (aPTT) and specific factor activity levels to ensure efficacy and safety [1, 4]. Notable challenges include managing the immunogenicity of the delivery vehicle and preventing the formation of inhibitors against the newly synthesized proteins [3].

Other names

Intrinsic pathway factor mRNACoagulation factor mRNAmRNA-based clotting factor replacementContact activation pathway mRNA

Exogenous mRNA is delivered to host cells, typically hepatocytes, where it is translated by the ribosome into a functional coagulation factor protein that is subsequently secreted into the blood to restore the intrinsic coagulation cascade.